August 2026
1. SCIBILIA R, Cleal B, Dickinson JK, Sethi J, et al
   Diabetes advocacy campaigns should focus on living a life, not fighting a battle.
   BMJ. 2026;394:e100525.
   

   >> Share

   
   
2. KRUGER N, Schneeweiss S, Wang SV
   Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.
   BMJ. 2026;394:e100011.
   

   >> Share

   
   
3. TANNE JH
   Doctors ejected from diabetes conference for criticising US administration face internal investigation.
   BMJ. 2026;394:e100475.
   

   >> Share

   
   July 2026
4. TANG H, Zhang B, Lu Y, Zhang D, et al
   Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation.
   BMJ. 2026;394:e100077.
   

   >> Share

   
   
5. EVANS L
   Life with type 1 diabetes is much more than numbers.
   BMJ. 2026;394:e278125.
   

   >> Share

   
   June 2026
6. WISE J
   Type 1 diabetes: Drug to delay onset approved for use in the NHS.
   BMJ. 2026;393:e100063.
   

   >> Share

   
   
7. TANNE JH
   Trump: ADA president elect resigns after US doctors are ejected from diabetes meeting.
   BMJ. 2026;393:e327847.
   

   >> Share

   
   
8. NATHAN DM
   American Diabetes Association controversy: Activism is necessary to protect scientific freedom.
   BMJ. 2026;393:e555118.
   

   >> Share

   
   
9. LANG K
   Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
   BMJ. 2026;393:e102036.
   

   >> Share

   
   
10. TANNE JH
    Trump: Diabetes doctors ejected from conference for handing out paper criticising US administration.
    BMJ. 2026;393:e511576.
    

    >> Share

    
    May 2026
11. VALABHJI J, Theodoraki A, Hope D
    Diabetic peripheral neuropathy: the broader complication burden.
    BMJ. 2026;393:s854.
    

    >> Share

    
    March 2026
12. HAMMAD H
    The wellness inspired rise of continuous glucose monitors for people without diabetes, including those with metabolic disorders.
    BMJ. 2026;392:s441.
    

    >> Share

    
    
13. FRIDMAN V, Elafros M, Eid S, Reynolds EL, et al
    Advances in the pathophysiology and treatment of diabetic peripheral neuropathy.
    BMJ. 2026;392:e081217.
    

    >> Share

    
    
14. IACOBUCCI G
    Diabetes patients dying in hospital from insulin mismanagement, safety watchdog warns.
    BMJ. 2026;392:s588.
    

    >> Share

    
    
15. CAI M, Choi T, Xie Y, Al-Aly Z, et al
    Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
    BMJ. 2026;392:e086886.
    

    >> Share

    
    February 2026
16. WISE J
    New weight loss pill outperforms oral semaglutide for diabetes patients, study reports.
    BMJ. 2026;392:s399.
    

    >> Share

    
    
17. WISE J
    Type 2 diabetes: SGLT-2 inhibitors should be offered as first line treatment, doctors are told.
    BMJ. 2026;392:s333.
    

    >> Share

    
    January 2026
18. ALLOTEY J, Coomar D, Ensor J, Ruiz-Calvo G, et al
    Effects of lifestyle interventions in pregnancy on gestational diabetes: individual participant data and network meta-analysis.
    BMJ. 2026;392:e084159.
    

    >> Share

    
    December 2025
19. O'DOWD A
    Diabetes prevention: Almost a million people access NHS scheme.
    BMJ. 2025;391:r2686.
    

    >> Share

    
    November 2025
20. LOGAN M
    Trump expands visa requirements to include diabetes and obesity.
    BMJ. 2025;391:r2400.
    

    >> Share

    
    October 2025
21. HONG B, Lee H, Jung K, Rhee SY, et al
    Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study.
    BMJ. 2025;391:e085196.
    

    >> Share

    
    
22. TAYLOR L
    Sixty seconds on . . . type 5 diabetes.
    BMJ. 2025;391:r2092.
    

    >> Share

    
    September 2025
23. MCCRAY BA, Stino AM, Davalos L, Quigley S, et al
    Atypical diabetic neuropathies.
    BMJ. 2025;390:e081109.
    

    >> Share

    
    
24. FARMER A, Patel K, Dambha-Miller H
    Once weekly insulin in type 2 diabetes.
    BMJ. 2025;390:r1931.
    

    >> Share

    
    
25. LUCEWICZ SAMARAWICKRAMA A, Pasupathy D
    Preventing gestational diabetes.
    BMJ. 2025;390:r1900.
    

    >> Share

    
    
26. SUJAN MJ, Skarstad HM, Rosvold G, Fougner SL, et al
    Time restricted eating and exercise training before and during pregnancy for people with increased risk of gestational diabetes: single centre randomised controlled trial (BEFORE THE BEGINNING).
    BMJ. 2025;390:e083398.
    

    >> Share

    
    
27. TAYLOR L
    WHO adds controversial cancer and diabetes treatments to essential medicines list.
    BMJ. 2025;390:r1881.
    

    >> Share

    
    August 2025
28. BOWIE K
    Type 2 diabetes: SGLT-2 inhibitors to be offered as first line treatment in major guidance "shake-up".
    BMJ. 2025;390:r1777.
    

    >> Share

    
    
29. KAR P
    Partha Kar: The Super Six diabetes care model offers lessons for shifting care into the community.
    BMJ. 2025;390:r1727.
    

    >> Share

    
    
30. BOWIE K
    Type 1 diabetes: UK approves first drug for delaying onset.
    BMJ. 2025;390:r1762.
    

    >> Share

    
    
31. THEODORAKI A
    Management of type 2 diabetes.
    BMJ. 2025;390:r1726.
    

    >> Share

    
    
32. AGARWAL A, Mustafa R, Manja V, Agoritsas T, et al
    Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.
    BMJ. 2025;390:e082071.
    

    >> Share

    
    
33. NONG K, Jeppesen BT, Shi Q, Agoritsas T, et al
    Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.
    BMJ. 2025;390:e083039.
    

    >> Share

    
    
34. MISRA A, Sattar N, Ghosh A, Nassar M, et al
    Type 2 diabetes in South Asians.
    BMJ. 2025;390:e079801.
    

    >> Share

    
    
35. IBSEN DB, Zhang Y
    Potatoes and risk of type 2 diabetes.
    BMJ. 2025;390:r1557.
    

    >> Share

    
    
36. MOUSAVI SM, Gu X, Imamura F, AlEssa HB, et al
    Total and specific potato intake and risk of type 2 diabetes: results from three US cohort studies and a substitution meta-analysis of prospective cohorts.
    BMJ. 2025;390:e082121.
    

    >> Share

    
    July 2025
37. NOLAN T
    Diabetes deprescribing . . . and other research.
    BMJ. 2025;390:r1365.
    

    >> Share

    
    
38. KOGA H
    Stigmatising language made me avoid diabetes care; meaningful engagement with people with diabetes is the answer.
    BMJ. 2025;390:r981.
    

    >> Share

    
    June 2025
39. KAR P
    Partha Kar: The spending review is an opportunity to reevaluate priorities in diabetes care.
    BMJ. 2025;389:r1175.
    

    >> Share

    
    
40. LIN J, Huang Y, Xu B, Gu X, et al
    Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.
    BMJ. 2025;389:e083735.
    

    >> Share

    
    April 2025
41. 
    Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.
    BMJ. 2025;389:r845.
    

    >> Share

    
    February 2025
42. SHAPIRO SB, Yin H, Yu OHY, Rej S, et al
    Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.
    BMJ. 2025;388:e080679.
    

    >> Share

    
    January 2025
43. HOPE D, Valabhji J
    SGLT2 inhibitors and dietary calorie restriction for type 2 diabetes remission.
    BMJ. 2025;388:r40.
    

    >> Share

    
    
44. LIU Y, Chen Y, Ma J, Lin J, et al
    Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
    BMJ. 2025;388:e081820.
    

    >> Share

    
    December 2024
45. MOTTELSON M, Helby J, Nordestgaard BG, Ellervik C, et al
    Mortality and risk of diabetes, liver disease, and heart disease in individuals with haemochromatosis HFE C282Y homozygosity and normal concentrations of iron, transferrin saturation, or ferritin: prospective cohort study.
    BMJ. 2024;387:e079147.
    

    >> Share

    
    
46. LIU B, Zong G, Zhu L, Hu Y, et al
    Chocolate intake and risk of type 2 diabetes: prospective cohort studies.
    BMJ. 2024;387:e078386.
    

    >> Share

    
    November 2024
47. IACOBUCCI G
    Diabetes: Global treatment gap is widening, study finds.
    BMJ. 2024;387:q2515.
    

    >> Share

    
    
48. SCIVIER M
    Quality care is needed for older people with diabetes in care homes-now and for the future.
    BMJ. 2024;387:q2471.
    

    >> Share

    
    
49. SVANSTROM H, Mkoma GF, Hviid A, Pasternak B, et al
    SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study.
    BMJ. 2024;387:e080925.
    

    >> Share

    
    October 2024
50. MCCORMICK N, Yokose C, Lu N, Wexler DJ, et al
    Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.
    BMJ. 2024;387:e080035.
    

    >> Share

    
    
51. ALKABBANI W, Suissa K, Gu KD, Cromer SJ, et al
    Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.
    BMJ. 2024;387:e080340.
    

    >> Share

    
    
52. MENG LC, van Gelder MMHJ, Chuang HM, Chen LK, et al
    Paternal metformin use and risk of congenital malformations in offspring in Norway and Taiwan: population based, cross national cohort study.
    BMJ. 2024;387:e080127.
    

    >> Share

    
    
53. LIU L, Ke W, Li H, Li F, et al
    Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
    BMJ. 2024;387:e080122.
    

    >> Share

    
    
54. AGARWAL A, Zeng X, Li S, Rayner D, et al
    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.
    BMJ. 2024;387:e080257.
    

    >> Share

    
    September 2024
55. WISE J
    Diabetes: Once weekly insulin could be as effective as daily injections, studies indicate.
    BMJ. 2024;386:q2005.
    

    >> Share

    
    
56. 
    Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
    BMJ. 2024;386:q1911.
    

    >> Share

    
    August 2024
57. TU SY, Shao SC, Loh CH, Huang HK, et al
    SGLT-2 inhibitors and dementia.
    BMJ. 2024;386:q1841.
    

    >> Share

    
    
58. MAHASE E
    Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
    BMJ. 2024;386:q1878.
    

    >> Share

    
    
59. SHIN A, Koo BK, Lee JY, Kang EH, et al
    Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
    BMJ. 2024;386:e079475.
    

    >> Share

    
    
60. KMIETOWICZ Z
    SGLT-2 inhibitors for diabetes may help prevent dementia, study finds.
    BMJ. 2024;386:q1875.
    

    >> Share

    
    
61. MAHASE E
    Diabetes: One in 10 patients on NHS's "soups and shakes" diet plan went into remission.
    BMJ. 2024;386:q1733.
    

    >> Share

    
    July 2024
62. MAHASE E
    Semaglutide: FDA publishes warning amid reports of patients overdosing.
    BMJ. 2024;386:q1696.
    

    >> Share

    
    
63. IACOBUCCI G
    Semaglutide: UK regulator approves drug for prevention of cardiovascular events.
    BMJ. 2024;386:q1660.
    

    >> Share

    
    
64. MAHASE E
    GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.
    BMJ. 2024;386:q1645.
    

    >> Share

    
    
65. LAL N
    India: Doctors report surge in use of off label GLP-1 agonists among rich.
    BMJ. 2024;386:q1605.
    

    >> Share

    
    
66. DYER C
    People with type 1 diabetes and disordered eating need joined-up care, says coroner after woman's death.
    BMJ. 2024;386:q1597.
    

    >> Share

    
    
67. VANDERPANT N, Ward E, Farrell E, Theodoraki A, et al
    Insulin for people with type 2 diabetes mellitus.
    BMJ. 2024;386:e078015.
    

    >> Share

    
    
68. WISE J
    Covid-19: Progression to clinical type 1 diabetes accelerated after infection, study suggests.
    BMJ. 2024;386:q1557.
    

    >> Share

    
    
69. SETHI J
    Use of language in diabetes: what's in a name?
    BMJ. 2024;386:q1446.
    

    >> Share

    
    June 2024
70. MAHASE E
    GLP-1 shortages will not resolve this year, EMA warns, amid concern over off-label use.
    BMJ. 2024;385:q1448.
    

    >> Share

    
    
71. FU EL, Wexler DJ, Cromer SJ, Bykov K, et al
    SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    BMJ. 2024;385:e078483.
    

    >> Share

    
    
72. DOBLE E, Farrow D
    We need to tackle the increasing mountain of wasted plastic and cardboard from diabetes technologies.
    BMJ. 2024;385:q1337.
    

    >> Share

    
    
73. ZHANG J, Li Y
    Increasing prevalence of type 1 diabetes in older age may be a good sign.
    BMJ. 2024;385:q1322.
    

    >> Share

    
    
74. YANG K, Yang X, Jin C, Ding S, et al
    Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study.
    BMJ. 2024;385:e078432.
    

    >> Share

    
    
75. 
    New advances in type 1 diabetes.
    BMJ. 2024;385:q1224.
    

    >> Share

    
    May 2024
76. JENKINS AJ, Ogle GD, Scibilia R, Schwarz P, et al
    People who need insulin are particularly vulnerable in disasters and conflicts.
    BMJ. 2024;385:q1109.
    

    >> Share

    
    
77. BIDULKA P, Lugo-Palacios DG, Carroll O, O'Neill S, et al
    Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    BMJ. 2024;385:e077097.
    

    >> Share

    
    April 2024
78. MAHASE E
    Diabetes UK defends partnership with Slimming World in face of criticism.
    BMJ. 2024;385:q962.
    

    >> Share

    
    
79. SIMMS-WILLIAMS N, Treves N, Yin H, Lu S, et al
    Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    BMJ. 2024;385:e078242.
    

    >> Share

    
    
80. NOLAN T
    The use of continuous glucose monitoring devices in non-diabetic adults ... and other research.
    BMJ. 2024;385:q859.
    

    >> Share

    
    
81. SETHI J
    Breaking free from the stigma of diabetes.
    BMJ. 2024;385:q890.
    

    >> Share

    
    
82. BOKINNI Y
    Barbados is in the grip of a diabetic foot amputation crisis.
    BMJ. 2024;385:q350.
    

    >> Share

    
    
83. PASTERNAK B, Wintzell V, Hviid A, Eliasson B, et al
    Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
    BMJ. 2024;385:e078225.
    

    >> Share

    
    March 2024
84. CHRISTIE B
    Charity calls for Scottish government to increase access to diabetes technology.
    BMJ. 2024;384:q755.
    

    >> Share

    
    
85. MAHASE E
    Type 1 diabetes: Randox removes adverts after claims that it was using fear to sell genetic test.
    BMJ. 2024;384:q744.
    

    >> Share

    
    
86. SAUL H, Deeney B, Swaithes L, Hounkpatin H, et al
    Even short periods of diabetes remission are linked to lower risk of heart attack and stroke.
    BMJ. 2024;384:q516.
    

    >> Share

    
    
87. TANNE JH
    FDA approves first over-the-counter blood glucose monitor for diabetes.
    BMJ. 2024;384:q611.
    

    >> Share

    
    
88. TANNE JH
    US food manufacturer can say that eating yogurt reduces risk of type 2 diabetes, says FDA.
    BMJ. 2024;384:q569.
    

    >> Share

    
    February 2024
89. LANE MM, Gamage E, Du S, Ashtree DN, et al
    Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses.
    BMJ. 2024;384:e077310.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share